HOOKIPA Pharma Inc., a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in preclinical studies for the treatment of human papillomavirus-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop arenavirus based therapeutics to treat hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was founded in 2011 and is headquartered in New York, New York.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone431-890-6360
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees56
Next Earnings Date8/19/2019 (Estimated)
OptionableNot Optionable
Hookipa Pharma (NASDAQ:HOOK) Frequently Asked Questions
What is Hookipa Pharma's stock symbol?
Hookipa Pharma trades on the NASDAQ under the ticker symbol "HOOK."
How were Hookipa Pharma's earnings last quarter?
Hookipa Pharma Inc (NASDAQ:HOOK) released its earnings results on Monday, May, 20th. The company reported ($9.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by $8.85. The company earned $2.24 million during the quarter, compared to analyst estimates of $0.50 million. View Hookipa Pharma's Earnings History.
When is Hookipa Pharma's next earnings date?
What price target have analysts set for HOOK?
4 Wall Street analysts have issued 1-year price objectives for Hookipa Pharma's shares. Their forecasts range from $17.00 to $23.00. On average, they expect Hookipa Pharma's share price to reach $20.00 in the next year. This suggests a possible upside of 120.8% from the stock's current price. View Analyst Price Targets for Hookipa Pharma.
What is the consensus analysts' recommendation for Hookipa Pharma?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Hookipa Pharma in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Hookipa Pharma.
Has Hookipa Pharma been receiving favorable news coverage?
Media stories about HOOK stock have been trending somewhat positive recently, according to InfoTrie Sentiment Analysis. The research group rates the sentiment of media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Hookipa Pharma earned a media sentiment score of 1.4 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the company's share price in the next several days. View News Stories for Hookipa Pharma.
Who are some of Hookipa Pharma's key competitors?
Some companies that are related to Hookipa Pharma include Y-mAbs Therapeutics (YMAB), Advanz Pharma (CXRXF), Kiniksa Pharmaceuticals (KNSA), MacroGenics (MGNX), Eagle Pharmaceuticals (EGRX), Kura Oncology (KURA), G1 Therapeutics (GTHX), Intra-Cellular Therapies (ITCI), Clovis Oncology (CLVS), CannTrust (CTST), Zymeworks (ZYME), Organogenesis (ORGO), Arvinas (ARVN), Odonate Therapeutics (ODT) and TG Therapeutics (TGTX).
What other stocks do shareholders of Hookipa Pharma own?
Who are Hookipa Pharma's key executives?
Hookipa Pharma's management team includes the folowing people:
- Mr. Joern Aldag, Pres, CEO & Director (Age 60)
- Mr. Daniel Pinschewer, Founder & Chief Scientific Officer (Age 44)
- Dr. Reinhard Kandera, CFO & Director (Age 50)
- Mr. Anders Lilja Ph.D., Sr. VP of Technical Devel. (Age 46)
- Mrs. Nina Waibel, Communications & Investor Relations Mang.
When did Hookipa Pharma IPO?
(HOOK) raised $100 million in an initial public offering on Thursday, April 18th 2019. The company issued 6,700,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, SVB Leerink and RBC Capital Markets acted as the underwriters for the IPO and Kempen was co-manager.
When does Hookipa Pharma's lock-up period expire?
Hookipa Pharma's lock-up period expires on Tuesday, October 15th. Hookipa Pharma had issued 6,000,000 shares in its initial public offering on April 18th. The total size of the offering was $84,000,000 based on an initial share price of $14.00. Shares of the company owned by major shareholders and company insiders will be eligible for trade following the end of the lock-up period.
How do I buy shares of Hookipa Pharma?
Shares of HOOK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Hookipa Pharma's stock price today?
One share of HOOK stock can currently be purchased for approximately $9.06.
How big of a company is Hookipa Pharma?
What is Hookipa Pharma's official website?
How can I contact Hookipa Pharma?
Hookipa Pharma's mailing address is 350 Fifth Avenue 72nd Floor Suite7240, New York NY, 10118. The company can be reached via phone at 431-890-6360 or via email at [email protected]
MarketBeat Community Rating for Hookipa Pharma (NASDAQ HOOK)
MarketBeat's community ratings are surveys of what our community members think about Hookipa Pharma and other stocks. Vote "Outperform" if you believe HOOK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HOOK will underperform the S&P 500 over the long term. You may vote once every thirty days.
